
Roche has announced new results from the Phase III studies of investigational medicine Ocrevus (ocrelizumab) studying relapsing multiple sclerosis (RMS) …

German pharma group Merck has earned a 7% bump in its sales, and a 10% boost in earnings before deductions, …
Merck KGaA encountered an uneven start to 2015, with robust sales in the first quarter offset by declines in key …

Biogen Idec has racked up another approval over the weekend after its latest multiple sclerosis treatment Plegridy gained FDA backing. …

Sanofi’s once-daily multiple sclerosis pill Aubagio has been authorised by European regulators, paving the way for it to continue its …

US regulators have given the green light for Genzyme’s Aubagio to treat patients with relapsing forms of multiple sclerosis (MS). …

The US Food and Drug Administration has asked Merck KGaA to undertake a ‘comprehensive and global assessment’ of its manufacturing …

The European Commission has approved an indication for multiple sclerosis treatment Rebif that treats early signs of the condition.This EC …
Lemtrada has beaten Merck Serono’s multiple sclerosis treatment Rebif in a new head-to-head trial, paving the way for regulatory submission …

Merck Serono has set up an international social network for multiple sclerosis patients, saying today’s pharma companies should go beyond …
German pharma company Merck has posted a modest rise in revenue amidst strong pharma growth. Revenues increased 2.1% to 7.7 …